I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice